Scarica l'app Stockscreener
49.65
3.37%
1.62
Dopo l'orario di chiusura:
49.81
0.16
+0.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AKRO Giù?
Forum
Previsione
Precedente Chiudi:
$48.03
Aprire:
$47.55
Volume 24 ore:
3.02M
Relative Volume:
2.24
Capitalizzazione di mercato:
$3.96B
Reddito:
-
Utile/perdita netta:
$-269.44M
Rapporto P/E:
-13.24
EPS:
-3.75
Flusso di cassa netto:
$-262.63M
1 W Prestazione:
+7.10%
1M Prestazione:
+15.36%
6M Prestazione:
+54.67%
1 anno Prestazione:
+171.16%
Intervallo 1D:
$47.17
$51.66
Intervallo di 1 settimana:
$44.94
$51.66
Portata 52W:
$17.86
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Nome
Akero Therapeutics Inc
Settore
Industria
Telefono
650-487-6488
Indirizzo
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Confronta AKRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
49.65 | 3.70B | 0 | -269.44M | -262.63M | -3.75 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-30 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-01-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-18 | Iniziato | Citigroup | Buy |
| 2024-04-22 | Ripresa | BofA Securities | Neutral |
| 2023-09-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Iniziato | UBS | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Iniziato | Guggenheim | Buy |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2020-07-01 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-02 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-10 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Evercore ISI | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
| 2019-07-15 | Iniziato | Jefferies | Buy |
| 2019-07-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Akero Therapeutics Inc Borsa (AKRO) Ultime notizie
Two Sigma Investments LP Increases Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
How to Take Advantage of moves in (AKRO) - news.stocktradersdaily.com
Akero Therapeutics (NASDAQ:AKRO) Trading 4.5% HigherShould You Buy? - MarketBeat
ProShare Advisors LLC Has $623,000 Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
BNP Paribas Financial Markets Sells 12,220 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Akero Therapeutics Inc. Stock Jumps Over 4%: What’s Powering This Biotech Surge? - Daily Chhattisgarh News
Akero Therapeutics (AKRO) Stock Climbs: Dissecting the Rally and What Lies Ahead - Daily Chhattisgarh News
2025-05-29 | Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation | NDAQ:AKRO | Press Release - Stockhouse
D. E. Shaw & Co. Inc. Sells 89,573 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Woodline Partners LP Grows Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Price Target Raised to $64.00 at Bank of America - MarketBeat
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Akero Therapeutics Readies Major Pipeline Updates for Jefferies Healthcare Conference Next Week - Stock Titan
BofA Adjusts Akero Therapeutics (AKRO) Price Target to $64 | AKR - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Akero Therapeutics (AKRO) Price Target Raised by B of A Securities | AKRO Stock News - GuruFocus
BofA Adjusts Akero Therapeutics (AKRO) Price Target to $64 | AKRO Stock News - GuruFocus
Akero Therapeutics (NASDAQ:AKRO) Shares Down 5.9% After Insider Selling - MarketBeat
Rafferty Asset Management LLC Sells 17,797 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
2025-05-25 | Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:AKRO | Press Release - Stockhouse
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus Rating of “Buy” from Brokerages - Defense World
D. E. Shaw & Co. Inc. Decreases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Tema Etfs LLC Makes New $894,000 Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics (AKRO) Considers Potential Sale Amid Strategi - GuruFocus
Deutsche Bank AG Has $7.62 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by RTW Investments LP - MarketBeat
Akero: FGF21 Advancement For MASH Targeting Presses On With Key Developments (NASDAQ:AKRO) - Seeking Alpha
Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today - Insider Monkey
Akero Therapeutics (AKRO) Weighs Sale Amid Takeover Interest - GuruFocus
Akero Therapeutics (AKRO) Considers Potential Sale Following Int - GuruFocus
Northern Trust Corp Buys 35,737 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero surges after report on plans for potential sale - Seeking Alpha
Akero Therapeutics (AKRO) Considers Potential Sale Following Interest | AKRO Stock News - GuruFocus
Cubist Systematic Strategies LLC Buys New Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero (AKRO) Shares Surge Amid Speculation of Potential Sale | AKRO Stock News - GuruFocus
MPM Bioimpact LLC Buys 68,073 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Janus Henderson Group PLC Decreases Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
66,000 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by Orbimed Advisors LLC - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out - ACCESS Newswire
Akero Therapeutics (NASDAQ:AKRO) Issues Earnings Results - MarketBeat
Algert Global LLC Lowers Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Northern Trust Corp Increases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
The Manufacturers Life Insurance Company Has $3.47 Million Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics Inc Azioni (AKRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):